OpenAI acquires Orchestra Bio to bring AI agents into drug development
OpenAI acquires Orchestra Bio to bring AI agents into drug development
AI Overview
OpenAI Group PBC has acquired Orchestra Bio, a San Francisco startup whose AI agents help pharmaceutical teams track development programs.
Why it matters
The deal shows how OpenAI plans to apply its Rosalind biology models to the slow, fragmented drug development pipeline, and it sits alongside Anthropic's own biotech acquisition.